Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has provided an update.
JCR Pharmaceuticals and Italy’s Italfarmaco have signed an exclusive licensing agreement granting JCR the rights to develop and commercialize the Duchenne muscular dystrophy drug givinostat in Japan, where it is not yet approved despite authorizations in the US, EU and UK. JCR will handle local clinical development and regulatory submissions, while the deal also establishes a broader strategic collaboration to pursue additional rare disease therapies, potentially including future R&D partnerships and cross-licensing. The move strengthens JCR’s rare disease portfolio and positions it as a key player in bringing an important DMD treatment to the Japanese market, though the financial impact on its current fiscal year results is still under review.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen748.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a Japan-based biopharmaceutical company focused on developing and commercializing therapies for rare diseases, leveraging proprietary platform technologies and a research and development pipeline aimed at addressing high unmet medical needs in specialized patient populations.
Average Trading Volume: 1,008,068
Technical Sentiment Signal: Hold
Current Market Cap: Yen89.22B
See more insights into 4552 stock on TipRanks’ Stock Analysis page.